enhanc cancer leadership
ew
resum coverag equal-weight rate pt
acquisit celgen make bristol top global cancer
compani see solid growth near-term includ
potenti upsid synergi bristol face key franchis
eros long-term await pipelin develop
invest thesi pt rate share equal-weight see
potenti earn upsid near-term driven bigger/fast cost
synergi realiz balanc patent eros mid-lat
uncertainti pipelin potenti pt base upon ep
offer dividend yield project compound-annual-growth-rate revenue
ep price-to-earnings multipl target bottom end peer rang
although offer above-averag ep growth
face steepest patent eros mid-lat among coverag
addit multipl close larg cap compani face
quick fact combin compani bristol extend cancer leadership solid
tumor ad celgen hematolog franchis pipelin approxim
celgen revenu exclud otezla hematolog includ
revlimid face gener eros
acquisit boost bristol revenue ep
estim pro forma debt repres
ebitda expect rapid de-lever due strong cash flow
rais estim reflect acquisit celgen model accret
rais ep in-lin manag guidanc
accret first full year accret rais ep
accret rais ep
model accret percentag peak fade thereaft driven
mainli celgen revenu declin post plu assum faster stand-alon
earn growth model cost synergi
out-year synergi project
slightli management vs project
pro forma revenu compound-annual-growth-rate compris
celg forecast ep compound-annual-growth-rate driven cost synergi
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
robust cash flow prospect enabl rapidli de-lev sustain exist
dividend polici pursu extern pipelin opportun project
gener oper cash flow four-year period
spend capital-expenditure period plu pay conting
valu right cvr impli close cash flow appli
toward reduc debt raised/assum celgen sustain
dividend annual pursu extern transact thu view bristol
strongli posit access extern innov help off-set long-term
eros major franchis revlimid eliqui opdivo due
generic/biosimilar competit recal earn call
manag reiter gross debt ebitda target
celgen bring sever interest pipelin opportun market
potenti key candid difficult predict due clinic profil
question rapidli evolv competit market reimburs
uncertainti manag indic combin compani would
six near-term product launch opportun potenti greater
revenu six five ozanimod reblozyl liso-cel inreb
come celgen model sale five product
includ sixth product roughli in-lin
consensu look forward detail clinic profil particularli
rel altern regimen
could wrong upsid bristol could deliv financi result
expect trial readout could encourag anticip
competit agent could falter downsid bristol could experi
merger integr issu trial could disappoint competitor drug could
base case ep price-to-earnings multipl discount group
averag bottom end group rang believ
multipl warrant near-term growth accret
balanc long-term uncertainti steepest patent cliff mid-
bull case ep
bull case ep
posit pipelin newsflow upsid financi surpris opdivo checkmate-
surprisingli match merck keytruda respect
result pipelin candid deliv clinic trial result exceed
expect revenu synergi upsid drive ep
engag value-enhanc strateg action
base case ep
base case ep
near-term accret growth balanc long-term uncertainti
assum opdivo result meet high bar set merck
keytruda deliv compel result ozanimod ibd result
bear case ep
bear case ep
pipelin financi fall short opdivo result
similar better merger integr problemat
synergi disappoint downsid revenu synergi yield ep
forecast
near-term growth rel inexpens
stock valuat key franchis set
compound-annual-growth-rate ep compound-annual-growth-rate
estim revenu
subject generic/biosimilar risk
bristol need add futur growth driver via
intern extern transact
higher/low model
quarterli result financi guidanc
result regulatori approv
psoriasi ozanimod ibd reblozyl md
car-t product
opdivo yervoy sale trend clinic
readout
immuno-oncolog news flow
competitor azn roch
extern busi develop
risk achiev price
upsid risk financi result
newsflow competitor disappoint
downsid risk financi shortfal
expect patent cliff disappoint
synergi
jan bristol celgen announc merger agreement
bristol would acquir celgen cash stock transact total valu
equival cash per celgen share base bristol close
stock price part transact celgen sharehold also
receiv conting valu right cvr upon fda approv three late-
stage pipelin product ozanimod liso-cel ide-cel within
specif time-fram see tradabl cvr ticker bqbbv issu
cvr current valu vs full valu
three product approv transact close novemb
bristol celgen sharehold respect combin
compani separ celgen conting valu right ticker celgz valu
per cvr relat celgen abraxan product
delist nasdaq global market expect begin trade
nyse symbol celgrt dec final aug celgen
enter purchas agreement acquir
global right celgen otezla cash
rational deal
bristol-celgen transact creat one largest oncolog compani
world total sale product target
solid tumor hematolog indic combin compani posit
leverag bristol strong immuno-oncolog io busi meaning growth
opportun maxim celgen late-stag hematolog pipelin extend
leadership immunolog inflammatori diseas particular bristol leverag
world-class commerci capabl acceler plan near-term launch
celgen de-risk late-stag pipelin product addit bristol reinvest strong
cash flow come year intern extern pipelin candid enhanc
regulatori statu report
outlin financi guidanc provid manag
accret first full year
synergi roughli synergi divid
financ
bm equiti issu celgen
cvr includ pipelin product ozanimod liso-cel ide-cel
tradeabl cvr ticker bqbbv valu per cvr
entitl holder receiv one-tim potenti payment cash upon
fda approv three drug partial credit
ozanimod decemb
liso-cel decemb
ide-cel march
manag summari execut bio
chairman board chief execut offic giovanni caforio
new bristol-my five major diseas area oncolog solid tumor
hematolog liquid tumor blood disord cardiovascular immunolog
fibrosi three largest market franchis revlimid revenu
eliqui total opdivo total
exhibit market product pipelin candid phase later yellow shade indic
product came celgen
exhibit upcom develop watch potenti key catalyst bold
opdivo yervoy chemo
opdivo cisplatin erbitux radiotherapi phase adjuv cancer
opdivo yervoy chemo
opdivo yervoy chemo
opdivo yervoy chemo
roch tecentriq nsclc final os readout rel pt
pivot trial data present r/r larg cell lymphoma
phase myelofibrosi data present
phase r/r multipl myeloma data present
pdufa rrm
pdufa low risk rs myelodysplast syndrom
pdufa r/r larg cell lymphoma base expect file
phase data crohn ulcer coliti
pdufa r/r multipl myeloma expect file
phase data psoriasi
pivot trial data r/r/ cll
opdivo lung kidney readout key immuno-oncolog event
lung look forward azn poseidon
look forward surviv data bristol astra zeneca
poseidon trial continu view keytruda result high bar
initi analys keytruda chemo show os hazard ratio hr
non-squam nsclc squamou nsclc
exhibit includ initi analys updat result
azn report posit top-lin result oct oct
announc opdivo yervoy two chemo cycl show overal surviv os
benefit vs chemo four cycl interim analysi oct
azn cover mark purcel announc imfinzi chemo
combin imfinzi tremelimumab chemo combin improv progression-
free surviv vs chemo alon poseidon
key question whether ad yervoy tremelimumab
part show lung surviv result opdivo low-dos yervoy compar
cross-trial keytruda monotherapi arguabl margin wors
cross-trial howev keytruda monotherapi hr hazard ratio
better opdivo monotherapi hr cross-trial poseidon unclear
azn press releas whether tremelimumab ad benefit top imfinzi chemo
cross-trial comparison also confound poseidon chemo differ
keytruda keynot trial impact difficult
predict poseidon use four cycl chemo three month concurr imfinzi
imfinzi tremelimumab addit chemo control arm allow six cycl
chemo use two cycl chemo six week concurr opdivo
yervoy keytruda trial allow four cycl
chemo instead six chemo control arm understand standard
care four cycl chemo
nsclc
nsclc
nsclc
cross-ov
chemo io
compani present data updat analysi data wclc reach statist signific
nsclc
cross-ov chemo
io
prescrib inform data updat analysi esmo
exhibit keytruda opdivo nsclc result
tc ic
nsclc
tc ic
cross-ov chemo io
tc tumour cell ic tumour-infiltr immun cell express central evalu ventana assay tc ic tc ic
compani present os data updat analysi wclc data updat analysi
kidney look forward javelin
keytruda inlyta current appear best rcc cross-trial rcc os
hazard ratio hr keytruda inlyta opdivo
yervoy bavencio inlyta javelin renal
tecentriq avastin immot intermediatepoor risk os hr
keytruda intermedi poor opdivo yervoy bavencio
succeed interim os still matur exhibit
bristol trial chanc show compar better result
keytruda trial involv cabometyx compar opdivo
cabometyx sutent cabometyx view potenti superior tki
inlyta cover jeff hung
exhibit rcc cross-trial comp trial use sutent activ compar
toxic profil difficult compar cross-trial opdivo yervoy combo appear
safeti patient treat
trae lead discontinu
nr reach indic n/a
best base grade trae bavencio inlyta lowest discontinu due
trae treatment-rel advers event trae grade opdivo yervoy vs
sutent vs bavencio inlyta vs sutent vs grade
trae keytruda inlyta vs sutent vs opdivo yervoy vs sutent
vs bavencio inlyta vs sutent vs trae lead
discontinu keytruda inlyta vs sutent vs opdivo yervoy vs
sutent vs bavencio inlyta vs sutent vs
pfizer/merck kgaa bavencio inlyta look compar keytruda inlyta
overal subgroup bavencio count pend final
javelin renal os readout notabl favor risk patient bavencio hr
consider better keytruda hr would also
highlight surviv rate keytruda bavencio appear
roughli compar approxim differ os benefit
arguabl may driven sutent arm surviv rate
compar roughli javelin renal last least k-m os
curv indic littl data censor month
appear still consider data censor month javelin renal
mean os curv month javelin renal could still
chang significantli merck kgaa cover joseph lockey
exhibit merck kaplan-mei plot overal surviv
exhibit pfizer/merck kgaa javelin renal kaplan-mei plot overal surviv
phase readout late earli
phase psoriasi efficaci bristol oral novel look highli
compel also appear signific safeti issu
efficaci safeti need confirm phase
bristol character inhibitor select
small molecul tyrosin kinas member jak janu kinas famili
regul immun inflamm cytokin signal henc inhibit
potenti treat varieti auto-immun diseas similar jak
inhibitor xeljanz lilli olumi oral drug approv psoriasi
celgen otezla approv methotrex gener cyclosporin
gener submit xeljanz fda issu ask safeti
analys
phase psoriasi data highli compel respond rate
doubl otezla cross-trial efficaci result appear fall bit short
newer inject especi mg qod mg qd dose
significantli lower includ
obviou concern safeti signal observ seriou advers event sae
observ two highest dose mg bid mg qd
patient arm includ placebo three highest dose arm
drug-rel mg bid mg bid mg qd compar
placebo discontinu due vs respect
frequent nasopharyng headach diarrhea nausea upper
run two phase single-dos trial patient liver kidney damag
understand uncommon oral drug liver trial enrol
patient expect complet august kidney trial enrol
patient expect complet decemb primari endpoint drug
concentr secondari endpoint advers event safeti trial
start februari
phase trial expect complet juli bristol ir said investor
expect first ph result late second start
registr trial
current enrol expect complet date juli trial includ
otezla activ compar disclos dose competit reason
theoret blockbust potenti psoriasisor otezla global sale
run rate current annual despit modest efficaci otezla approv
global sale yoy growth otezla efficaci consider
less xeljanz taltz addit psoriasi
evalu phase trial psoriat arthriti primari complet april lupu
primari complet juli moderatesever crohn diseas primari
watch potenti competitor dual candid
phase trial psoriasi alopecia ibd avail clinic data
insuffici compar complet phase trial psoriasi
march yet disclos data phase trial show encourag
decreas pasi score especi mg dosemaxim mean chang pasi
score mg mg week baselin pasi
disclos phase trial alopecia primari complet jan
phase trial crohn diseas primari complet feb phase
trial ulcer coliti primari complet dec asid pf-
differ jak receiv breakthrough
therapi design fda alopecia
exhibit cross-trial comparison plaqu psoriasi oral data week oral otezla data week oral xeljanz
week inj taltz data week note pfizer abandon xeljanz psoriasi awar jak develop
opt pivot
exhibit summari phase safeti
celgen pipelin includ number high-profil candid
signific opportun uncertainti abound
celgen bring sever pipelin candid sever face competit
posit commerci potenti uncertainti celgen number excit
new hematolog treatment candid look forward detail
benefit/risk profil particularli rel altern regimen given rapidli evolv
ozanimod me-too arguabl better safeti multipl sclerosi although
offer potenti new mechan ibd ulcer coliti crohn diseas
efficaci profil ibd may quit match altern treatment
reblozyl luspatercept offer compel option treatment
anemia esa-refractory/inelig rs md pdufa apr beta-
thalassemia approv nov howev potenti esa-nav md
unclear look forward data vs epogen command
addit myelofibrosi anemia treatment could signific opportun
phase readout would year away
liso-cel potenti transform car-t larg b-cell
lymphoma reimburs uncertainti could constrain adopt
potenti outpati vs icu use unclear
bcma car-t agent ide-cel hot new target
multipl myeloma howev competit landscap like fierc
least bcma target agent develop current car-t
need deliv highli compel efficaci justifi potenti cost usag
inreb fedratinib intermedi high-risk myelofibrosi approv aug
unlik move front-lin due black box warn encephalopathi
exhibit summari tabl key pipelin product
relaps form ms pdufa date
relapsing-remit ms ema decis expect
td beta- thal fda approv
md esa refractory/inelig rs pdufa date
md esa refractory/inelig rs td beta-th ema decis
expect
us ex-u toward end
r/r dlbcl fda submiss expect approv expect
rrmm fda submiss expect approv expect
high-risk primari secondari pet ppv
myelofibrosi approv
high-risk primari secondari pet ppv
myelofibrosi eu mma submiss
aml mainten therapi plan regulatori sumbmiss
us yr data biosimilar exclus
date approv
ex-u yr data biosimilar exclus
date approv
us yr data biosimilar exclus
date approv
ex-u yr data biosimilar exclus
date approv
ex-u mid late
md myelodyplast syndrom td transfusion-depend rs ring sideroblast postessenti thrombocythemia myelofibrosi pet-mf postpolycythemia vera myelofibrosi ppv-mf rrmm relaps
refractori multipl myeloma r/r dlbcl relapsed/refractori diffus larg b-cell lymphoma ms multipl sclerosi aml acut myeloid leukemia
ozanimod appear me-too better cardiac safeti multipl sclerosi
although offer potenti new mechan ibd ulcer coliti crohn
diseas efficaci profil ibd may match altern treatment
ozanimod sphingosin agonist
believ caus lymphocyt sequestr lymph node presum reduc
migrat central nervou system drug gilenya mayzent
current sold novarti novarti cover mark purcel
pdfua date relaps form multipl sclerosi march
ema decis relapsing-remit multipl sclerosi rrm expect
phase north trial data ulcer coliti expect
estim sale see low risk ozanimod approv given
panel expect fda approv novarti gilenya mayzent
mechan howev also believ ozanimod receiv gilenya-lik
class label requir first-dos monitor note celgen management project
peak sale
expect label similar gilenya rrm competit landscap fairli
crowd base phase radianc sunbeam trial data ozanimod similar
efficaci gilenya exhibit lower incid class side effect
cardiac liver compar gilenyather report case
symptomat bradycardia degre heart block nonetheless expect ozanimod
requir first dose monitor like gilenya furthermor competit
intensifi significantli recent approv novarti mayzent siponimod
merck kgaa mavenclad oral cladribin well potenti entri gener gilenya
inflammatori bowel diseas ibd repres signific opportun phase
data uninspir novel mechan may prove better manag
state ozanimod could first-in-class drug howev expect
ibd competit landscap becom increasingli crowd novel mechan
develop includ arena etrasimod oral gilead filgotinib jak oral
mirikizumab inj exhibit gilead cover matthew harrison
arena cover
exhibit pipelin drug crohn diseas cd ulcer coliti uc
modest expect ozanimod ibd phase touchston studi
ulcer coliti uc ozanimod vs placebo achiev clinic remiss rate
vs compar cross-trial phase trial result simponi vs
entyvio vs appear wors etrasimod vs cross-trial
comparison challenging induct period readout differ
wk etrasimod vs wk ozanimod regard safeti think
ozanimid etrasimod compar low seriou advers event
advers cardiac event exhibit exhibit ozanimod phase north
trial expect readout mid arena advanc phase uc trial
still recruit primari complet date crohn diseas ozanimod
phase yellowston primari complet expect feb final
complet apr arena plan initi phase asid
celgen previous discontinu phase trial crohn diseas differ
molecul mongersen oral antisens oligonucleotid
exhibit oral agent efficaci safeti data comparison uc ozanimod vs arena
moder sever uc
reduct mayo clinic score
etrasimod data ozanimod data nejm
exhibit clinic remiss rate approv biolog uc
note head-to-head studi comparison
reblozyl luspatercept offer compel option treatment anemia
esa-refractory/inelig rs md pdufa apr beta-thalassemia
approv nov howev potenti esa-nav md unclear
look forward data vs epogen command addit myelofibrosi
anemia treatment could signific opportun phase readout year
reblozyl erythroid matur agent neutral select tgf-beta superfamili
ligand inhibit aberr signal promot late-stag erythropoiesi
matur design treat patient seriou blood disord
associ ineffect erythropoiesi reblozyl jointli develop celgen
acceleron cover jeff hung acceleron stand receiv low mid
royalti global sale acceleron celgen co-promot reblozyl north
america celgen pay sale market expens
depend beta-th indic approv fda
md pdufa date april phase medalist
ema decis md medalist beta-th believ expect
phase myelofibrosi data present dec
phase command esa-na md primari complet date april
phase beyond non-transfus depend ntd beta-th primari
complet date
estim sale expect launch transfusion-depend
beta-th believ launch md command launch non-
transfus depend beta-th beyond model assum reblozyl
gain limit market share esa-na md see risk
safeti signal larger phase trial believ un-diagnos patient may
treat diseas less sever celgen management previous state
believ reblozyl could reach peak sale md beta-th
exhibit reblozyl luspatercept celgen estim peak sale appear optimist view
see reblozyl captur signific market share esa refractory/intoler
treatment anemia low-risk md patient driven lack altern
compel clinic data competit come soon medalist rebloyzl vs
placebo reblozyl hit primari secondari endpoint transfus
independ rbc-ti erythroid respons hi-e compar placebo low-
risk md set celgen run phase command head head trial vs esa
standard care primari complet date april think command
like succeed base medalist phase pace-md trial show
high percentag patient achiev transfus independ erythroid
respons exhibit believ reblozyl harder time gain
signific share therapi asid acceleron management state imetelstat
develop cover potenti direct competitor md could
becom competitor md rs segment depend phase imerg
primari studi complet date aug may
exhibit celgen vision luspatercept lower-risk md
trae lead death
progress aml
medalist data pace-md data eha
beta-thalassemia market potenti limit geograph constraint patient
mostli concentr greec arabian countri may limit
pricing/reimburs reblozyl asid reblozyl approv
drug therapi anemia due beta-thalassemia
posit data mf could potenti drive futur growth addit
data show transfusion-depend patient achiev primari endpoint
transfusion-independ consecut week management indic
respons rate would consid success hand
patient transfusion-depend patient achiev primari endpoint
reblozyl alon jakafi known caus anemia less like help
reduc anemia current phase give result acceleron would like advanc
combo therapi subsequ studi transfusion-depend patient
subgroup await detail monotherapi cohort dec
jakafi approv treat adult intermedi high-risk mf
approv therapi anemia mf mf patient jakafi need lower
dose anemia cover vikram purohit
exhibit phase medalist lower-risk md rs
exhibit phase command lower-risk md
exhibit phase believ transfusion-depend beta-th
exhibit phase beyond non-transfusion-depend beta-th
liso-cel potenti transform car-t larg b-cell lymphoma
reimburs uncertainti could constrain adopt potenti outpati
vs icu use unclear
liso-cel second gener car-t cell util co-stimulatori
domain aim target kill non-hodgkin lymphoma cell initi t-cell
activ antitumor activ origin develop juno
therapeut strateg collabor celgen develop cell-bas
therapi cancer autoimmun diseas celgen acquir
march gain full right liso-cel pipelin engin t-cell
therapi includ anti-bcma t-cell multipl myeloma see bcma
fda regulatori submiss r/r dlbcl therapi on-track
transcend approv expect
pivot phase transcend r/r dlbcl present
pivot phase r/r cll primari complet date
estim sale assum approxim sale
although product efficaci profil compel face reimburs uncertainti
potenti altern therapi develop note celgen management
indic liso-cel could potenti peak sale car-t therapi
gener modest sale date anticip due reimburs
adopt constraint yescarta gener sale approv oct
dlbcl nv kymriah gener approv may dlbcl
aug acut lymphoblast leukemia relat note cvr depend
us dlbcl approv dec cover matthew harrison nv
cover mark purcel
exhibit list liso-cel trial dlbcl cll
r/r dlbcl data report abstract show
compel efficaci superior safeti profil cross-trial yescarta kymriah
liso-cel succeed primari secondari end point
particular liso-cel show complet respons cr rate compar
yescarta cr rate better kymriah cr rate importantli
liso-cel treat patient much lower rate cytokin releas syndrom
neurotox compar yescarta kymriah rate grade grade
 liso-cel yescarta kymriah rate
neurotox liso-cel yescarta
kymriah exhibit cross-trial comparison difficult subject
receiv bridg chemotherapi contain diseas await manufactur
manufactur delay failur affect subject die drop
trial progress diseas bridg chemotherapi could increas
risk grade advers event
exhibit car-t therapi efficaci safeti data comparison liso-cel vs yescarta vs
trae pt
grade grade
treat tocilizumab
death attribut
ne grade grade
data abstract juliet data fda label
like car-t therapi liso-cel face reimburs uncertainti kymriah nv
yescarta approv estim less
peopl treat car-t therapi march uptak
hamper current reimburs complex hospit may even
abl break-even due low singl payment drg inpati infus
current determin annual averag hospit cost
preced year inadequ variabl reimburs new technolog
add-on outlier payment car-t therapi specif drg code
current reimburs polici may take year reimburs
inpati infus updat contrast financi incent better align
hospit outpati set howev car-t treatment carri risk
neurotox requir hospit stay critic care support
patient current receiv car-t hospit addit even car-t
administ outpati set medicar would reimburs therapi
lower inpati rate hospit admiss occur within three day treatment
potenti liso-cel use outpati set key drive market adopt given
liso-cel lower rate sever neurotox compar yescarta
kymriah management argu treatment outpati set unclear
much better safeti profil need order support liso-cel outpati
use apc outpati drg equival could drive signific market uptak
updat t-cell reimburs polici higher reimburs
nationwid coverag reimburs still inadequ cover fda
approv t-cell therapi nationwid healthcar facil inpati
outpati facil enrol fda risk evalu mitig strategi
rem program therapi also pay certain off-label use
therapi support clinic research appear select peer-review medic
journal off-label use deem reason necessari addit
new polici set increas margin rate new technolog add-on payment
t-cell therapi went effect oct
increas wage index rural hospit fiscal year polici may
help car-t adopt american societi hematolog releas statement
state unfortun broad coverag polici pair poor reimburs leav
institut difficult posit requir cover therapi continu
receiv inadequ payment cover cost associ
exhibit liso-cel phase transcend nhl relaps refractori diffus larg b-cell
exhibit liso-cel phase chronic lymphocyt leukemia cll
bcma hot new target multipl myeloma howev competit landscap
like fierc least bcma target agent develop
current car-t need deliv highli compel efficaci justifi
potenti cost usag complex
ide-cel develop partnership cover matthew
harrison chimer antigen receptor t-cell therapi bind b-cell
matur antigen bcma surfac multipl myeloma mm cell
lead cell apoptosi collabor agreement celgen
share profit cost equal develop commerci
us celgen respons cost develop
commerci ex-u market pay tier royalti rate
rang mid-singl digit low-teen base percentag net sale ex-u
fda submiss relaps refractori multipl myeloma rrmm
expect approv expect
phase karmma updat data relaps refractori multipl myeloma
rrmm expect
initi phase newli diagnos multipl myeloma ndmm trial
plan
phase rrmm updat data present
estim sale unsur first-mov advantag
given number competitor current develop particular although car-
therapi shown robust durabl respons test indic
also limit toxic manufactur complex reimburs challeng see
liso-cel section end compani develop newer
gener antibodi differ modal includ antibody-drug conjug
bispecif antibodi tend less toxic requir
complex manufactur discuss note celgen management project
peak sale
forthcom bcma updat highlight signific competit activ
 car-t mani competit agent
demonstr high orr report matthew harrison compar
long-term follow-up addit patient data need
conclus comparison management expect provid info view
publish abstract data similar exhibit safeti efficaci
data drug interest includ previous publish data comparison note
unlik car-t therapi yescarta kymriah larg b-cell lymphoma
multipl myeloma cur therapi design induc
long-term remiss prolong progression-fre surviv gsk cover
median rang follow-up
prior therapi median
trae pt
grade grade
ne grade grade
data nejm data blood cancer journal data
move earlier line treatment challeng critic success
crowd market given hyper-competit environ bcma product
develop concern potenti dis-intermedi
bispecif antibodi likelihood treatment move earlier
differ anti-bcma regimen includ car-t therapi bispecif antibodi
present
see gsk belantamab mafodotin potenti major competit threat
given first mover advantag posit headlin submiss
expect mm better safeti profil base studi
ne observ advantag potenti use
inject trial includ inject iv await detail data orr
expect appear given particip slightli sicker
asid celgen bispecif antibodi
bcma cell engag data still earli trial
primari complet date juli gsk celgen
program aim move respect bcma agent earlier treatment line
present better econom opportun
mention split half revenu per
partnership agreement hand bristol econom
evolv phase trial relaps and/or refractori multipl myeloma
rrmm primari studi complet date
earli safeti efficaci data encourag long-term data need
data last present achiev orr
good partial respons vgpr better rate percent patient
grade cytokin releas syndrom neurotox grade
enrol continu order optim doze phase await addit
patient data longer follow-up see differenti appear
year behind refractori set vs
exhibit pivot trial karmma multipl myeloma
exhibit phase multipl myeloma
inreb intermedi high-risk myelofibrosi approv aug unlik
move front-lin due black box warn encephalopathi
inreb oral janu kinas inhibitor also inhibit fms-like-
tyrosin kinas block downstream signal jak-stat lead
inhibit cell prolifer induc cell apoptosi
inreb approv fda aug patient
high-risk primari secondari post-essenti thrombocythemia post-
eu mma submiss high-risk primari secondari post-
essenti thrombocythemia post-polycythemia vera myelofibrosi expect
phase freedom singl arm inreb vs best avail
therapi intermediate- high-risk myelofibrosi patient resist intoler
ruxolitinib freedom primari studi complet date jun
primari complet date
estim sale expect inreb captur sizabl share
mf target symptomat mf patient fail prior jakafi treatment note
celgen manag project peak sale
move frontlin treatment unlik due blackbox warn
encephalopathi see lack head-to-head trial comparison vs jakafi
mechanist see inreb somewhat distinct jakafi ruxolitinib
inreb select inhibitor also known inhibit wherea
jakafi equal potent clinic inreb shown
effect reduc spleen size resist intoler patient
comparison jakafi global sale grow
blackbox warn seriou fatal encephalopathi includ wernick limit
sale potenti celg acquir inreb fedratinib via acqusit impact
earli sanofi run trial fedratinib stop
develop follow suspect case wernick encephalopathi
impact acquir fedratinib sanofi restart program fda
ultim lift clinic hold eight case suspect
one clear case subsequ resolv two month
treatment iv thiamin
exhibit unmet need myelofibrosi
oral formul vidaza azacitidin dna hypomethyl agent
posit top-line result announc sept phase quazar
studi mainten therapi patient newli diagnos acut
myeloid leukemia aml detail result plan late-break
abstract vidaza went gener us patent exclus set expir
ex-u vidaza azacitidin inject sale includ
us
aml mainten therapi regulatori submiss plan begin
long-term financi outlook uncertain
mid-lat decad outlook cloud patent loss pipelin
estim revenu face generics/biosimilar
competit mid-lat
revlimid gener set enter market start march limit volum
full volum gener start jan estim revlimid account
total revenu yoy sale growth
model revlimid constitut
eliqui gener expect may us ex-u model eliqui
sale total grow total
opdivo could face biosimilar competit us model opdivo
sale total grow total
exhibit patent cliff order revenu exposur grey row small molecul white row biolog gener face less
total
orencia lose exclus unclear if/when could face biosimilar competit difficult copi complex fusion protein biosimilar current develop
growth in-lin product pipelin potenti depend upon clinic
modest expect opdivo readout lung renal cancer
expect opdivo show superior result keytruda cross-trial opdivo lung
kidney readout binari event section adjuv trial readout
celgen bring sever pipelin candid sever face competit
posit commerci potenti uncertainti celgen number excit
new hematolog treatment candid await detail benefit/risk
profil particularli rel altern regimen given rapidli evolv competit
landscap separ bristol highli compel profil await
confirm ph competit develop includ result
look forward greater pipelin clariti next year
chairman board chief execut offic
giovanni caforio ceo sinc may serv
compani board director sinc june may assum role
chairman board prior becom ceo giovanni serv chief oper offic
respons lead fulli integr world-wide commerci organ
compani wide function enterpris servic global manufactur suppli
preced work compani chief commerci offic giovanni
join bristol-my squibb vice presid gener manag itali
world-wide medicin group assum ad respons greec israel
south east europ appoint senior vice
presid european market brand commerci reloc
us assum role senior vice presid oncolog
name senior vice presid global commerci oncolog immunolog
becom presid compani organ prior join
bristol-my squibb giovanni spent year number
david elkin chief offic respons global busi oper
includ busi insight analyt global financ global procur
david join celgen juli sever year johnson johnson
serv chief offic compani consum product medic
devic corpor function prior experi includ evp chief
financi offic becton dickinson compani public global medic technolog
compani held role increas respons astrazeneca
began career financ boe compani
christoph boerner chief commerci offic bristol-my squibb
lead commerci strategi execut across geographi previou role
chri head intern market bristol-my squibb account
commerci activ ex-u market join compani februari
prior join bristol-my squibb chri serv execut vice presid
commerci inc led commerci activ
compani well senior vice presid commerci vice presid
market join chri work dendreon corpor
led market team work genentech
member roch group serv varieti commerci role includ
director market avastin prior genentech work mckinsey
compani serv global pharmaceut biotechnolog client
nadim ahm lead global hematolog franchis respons commerci
strategi execut activ around world also provid overal leadership
compani cell therapi busi nadim also overse hematolog medic
affair market access function nadim bring year pharmaceut
industri experi join bm celgen recent serv
presid global hematolog oncolog previous hold sever
leader role includ gener manag hematolog oncolog prior
global head market compani multipl myeloma franchis
celgen held posit increas respons clinic develop medic
affair global market glaxosmithklin
rupert vessey ch phil lead research earli
develop overse advanc promis program technolog
asset across therapeut area discoveri proof-of-concept also
work close busi develop identifi extern sourc innov
rupert join bm celgen serv presid compani
research earli develop organ prior join celgen rupert
spent ten year merck respons numer drug develop
program held leadership role compani earli develop discoveri
scienc drug discoveri informat group well respiratori
immunolog franchis prior time merck spent five year glaxosmithklin
involv drug discoveri experiment medicin earli clinic develop
therapeut respiratori immun diseas
samit hirawat overse late-stag product develop across therapeut
area role samit organ focu enabl rapid progress
deliveri late-stag asset proof-of-concept commerci
world-class clinic trial design oper samit join bm extens
drug develop experi recent serv execut vice presid
head oncolog develop novarti previous led clinic develop
program multipl indic pfizer/pharmacia corpor
forma cog net synergi
pre-tax cog synergi celg cost
project cog synergi total synergi
celg stock comp expens celg exclud non-gaap includ
forma sg net synergi excl celg stock comp exp
pre-tax sg synergi celg sg excl stock comp exp
project sg synergi total synergi
forma net synergi excl celg stock comp exp
pre-tax synergi celg excl stock comp exp
project synergi total synergi
synergi total celg oper cost excl celg stock comp exp
synergi total bmi celg oper cost excl celg stock comp exp
synergi peak guidanc synergi
forma oper cost net synergi incl celg stock comp exp
forma oper incom net synergi incl celg stock comp exp
net interest expense/ incom pro forma
celg synergi net interest
new share issu
pt base upon ep see potenti earn upsid
near-term driven bigger/fast cost synergi realiz balanc
key franchis patent eros mid-lat uncertainti pipelin potenti
henc believ multipl bottom end rang peer warrant
given long term eros risk pro forma pt multipl in-lin certain
larg cap compani similarli challeng long term growth outlooksi
alexion cover matthew harrison trade ep
estim revenu could face generics/biosimilar competit
mid-lat greatest exposur among coverag univers revlimid
total revenu gener set enter market start march
limit volum full volum gener start jan eliqui total
gener expect may us ex-u opdivo total
could face biosimilar competit us long-term outlook highli
uncertain detail
price
price
price
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
exhibit forward price-to-earnings multipl contract due long-term growth
exhibit price-to-earnings multipl vs us major pharma past five year
exhibit incom statement margin valuat
sg sale
 sale
exhibit balanc sheet statement
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
